Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
1. An isolated GPRC5D×CD3 bispecific antibody comprising:
a) a first heavy chain (HC1);
b) a second heavy chain (HC2);
c) a first light chain (LC1); and
d) a second light chain (LC2),
wherein the HC 1 and the LC 1 pair to form a first antigen-binding site that specifically binds CD3, and the HC2 and the LC2 pair to form a second antigen-binding site that specifically binds GPRC5D; wherein the HC1 comprises the amino acid sequence of SEQ ID NO: 99, and the LC1 comprises the amino acid sequence of SEQ ID NO: 100, wherein the HC2 comprises the amino acid sequence of SEQ ID NO: 55, and the LC2 comprises the amino acid sequence of SEQ ID NO: 58.
2. The isolated GPRC5D×CD3 bispecific antibody of claim 1 wherein the antibody is IgG4 isotype.
3. The isolated GPRC5D×CD3 bispecific antibody of claim 1 , wherein the HC2 further comprises the amino acid sequence of SEQ ID NO: 59.
4. The isolated GPRC5D×CD3 bispecific antibody of claim 1 , wherein the antibody binds GPRC5D on the surface of human myeloma cells.
5. The isolated GPRC5D×CD3 bispecific antibody of claim 1 , wherein the antibody binds GPRC5D on the surface of human multiple myeloma cells.
6. The isolated GPRC5D×CD3 bispecific antibody of claim 1 , wherein the antibody induces human T cell activation in vitro with an EC 50 of less than about 0.22 nM.
7. The isolated GPRC5D×CD3 bispecific antibody of claim 1 , wherein the antibody induces T-cell dependent cytotoxicity of GPRC5D-expressing cells in vitro with an EC 50 of less than about 0.89 nM.
8. An isolated cell expressing the isolated GPRC5D×CD3 bispecific antibody of claim 1 .
9. The isolated cell of claim 8 , wherein the cell is a hybridoma.
10. The isolated cell of claim 8 , wherein the GPRC5D×CD3 bispecific antibody is recombinantly produced.
11. A method for treating a subject having cancer, the method comprising:
administering a therapeutically effective amount of the isolated GPRC5D×CD3 bispecific antibody of claim 1 to a patient in need thereof for a time sufficient to treat the cancer.
12. A method for inhibiting growth or proliferation of cancer cells, the method comprising:
administering a therapeutically effective amount of the isolated GPRC5D×CD3 bispecific antibody of claim 1 for a time sufficient to inhibit the growth or proliferation of cancer cells.
13. A method of redirecting a T cell to a GPRC5D-expressing cancer cell, the method comprising:
administering a therapeutically effective amount of the isolated GPRC5D×CD3 bispecific antibody of claim 1 for a time sufficient to redirect a T cell to a cancer.
14. The method of claim 11 , wherein the cancer is a hematological cancer.
15. The method of claim 14 , wherein the hematological cancer is a GPRC5D-expressing B cell cancer.
16. The method of claim 15 , wherein the GPRC5D-expressing B cell cancer is multiple myeloma.
17. The method of claim 11 , wherein the method further comprises administering a second therapeutic agent.
18. The method of claim 17 , wherein the second therapeutic agent is a chemotherapeutic agent or a targeted anti-cancer therapy.
19. The method of claim 18 , wherein the chemotherapeutic agent is cytarabine, an anthracycline, histamine dihydrochloride, or interleukin 2.
20. The method of claim 18 , wherein the second therapeutic agent is administered to said subject simultaneously with, sequentially, or separately from the bispecific antibody.
21. A pharmaceutical composition comprising the isolated GPRC5D×CD3 bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.
22. A method for generating the isolated GPRC5D×CD3 bispecific antibody of claim 1 , the method comprising culturing a cell expressing the isolated GPRC5D×CD3 bispecific antibody under conditions sufficient to produce the bispecific antibody.
23. An isolated synthetic polynucleotide encoding the isolated GPRC5D×CD3 bispecific antibody of claim 1 .
24. A kit comprising the isolated GPRC5D×CD3 bispecific antibody of claim 1 and packaging for the same.
25. A kit comprising the isolated synthetic polynucleotide of claim 23 and packaging for the same.